Drugs / maveropepimut-S
maveropepimut-S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03349450 | Mar 2018 → Oct 2021 | diffuse large B-cell lymphoma | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | maveropepimut-S | “treated with maveropepimut-S (MVP-S, previously DPX-Survivac) a survivin directed T cell educating therapy, pembrolizumab, and intermittent low-dose cyclophosphamide.” PMID 37157906 ↗ May 2023 |
| Known as | DPX-Survivac | “treated with maveropepimut-S (MVP-S, previously DPX-Survivac) a survivin directed T cell educating therapy, pembrolizumab, and intermittent low-dose cyclophosphamide.” PMID 37157906 ↗ May 2023 |
| Known as | MVP-S | “treated with maveropepimut-S (MVP-S, previously DPX-Survivac) a survivin directed T cell educating therapy, pembrolizumab, and intermittent low-dose cyclophosphamide.” PMID 37157906 ↗ May 2023 |
| Route | Subcutaneous | “All injections will be given under the skin of the upper thigh.” NCT03349450 ↗ |